|
5.
NET LOSS PER COMMON SHARE
The
following table reconciles the weighted-average shares outstanding for basic and diluted net loss per share for the three and nine months
ended September 30, 2022 and 2021:
SCHEDULE
OF LOSSES PER SHARE, BASIC AND DILUTED
| |
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
| |
|
Three
Months Ended |
|
|
Nine
Months Ended |
|
| |
|
September
30, |
|
|
September
30, |
|
| |
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
| |
|
($
in thousands, except share and per share amounts) |
|
| Basic
and Diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net
loss attributable to common shareholders |
|
$ |
(2,793 |
) |
|
$ |
(2,137 |
) |
|
$ |
(6,729 |
) |
|
$ |
(11,094 |
) |
| Weighted-average common shares used to compute basic and diluted
loss per share |
|
|
15,148,721 |
|
|
|
14,737,103 |
|
|
|
15,070,913 |
|
|
|
14,419,968 |
|
| Net
loss attributable to common shareholders per share - basic and diluted |
|
$ |
(0.18 |
) |
|
$ |
(0.15 |
) |
|
$ |
(0.45 |
) |
|
$ |
(0.77 |
) |
At
September 30, 2022, the 480,526 unvested equity restricted stock units (“RSUs”) as discussed in Note 12 and 1,253,489 unexercised
warrants expiring between October 2022 and September 2023 with exercise prices between $3.92 to $10.00 have been excluded from the above
calculations as they were anti-dilutive. At September 30, 2021, the 280,496 unvested equity RSUs and 3,152,140 unexercised warrants have
been excluded from the above calculations as they were anti-dilutive. Vested RSUs, vested restricted shares and exercised warrants have
been included in the above calculations.
|